Definium Therapeutics Overview
- Year Founded
-
2019
- Status
-
Public
- Employees
-
106
- Stock Symbol
-
DFTX
- Investments
-
3
- Share Price
-
$32.08
- (As of Friday Closing)
Definium Therapeutics General Information
Description
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
Contact Information
Website
definiumtx.comCorporate Office
- One World Trade Center
- Suite 8500
- New York, NY 10007
- United States
Corporate Office
- One World Trade Center
- Suite 8500
- New York, NY 10007
- United States
Definium Therapeutics Stock Performance
As of 13-Nov-2026, Definium Therapeutics’s stock price is $32.08. Its current market cap is $4.39B with 137M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $32.08 | $33.00 | $10.46 - $49.70 | $4.39B | 137M | 1.98M | -$2.92 |
Definium Therapeutics Financials Summary
As of 30-Sep-2026, Definium Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 4,066,594 | 1,150,354 | 239,416 | 42,110 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (353,259) | (189,271) | (117,427) | (97,234) |
| Net Income | (337,481) | (183,793) | (108,679) | (95,732) |
| Total Assets | 1,074,283 | 440,100 | 302,151 | 124,541 |
| Total Debt | 36,661 | 40,579 | 21,854 | 14,129 |
Definium Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Definium Therapeutics Comparisons
Industry
Financing
Details
Definium Therapeutics Competitors (8)
One of Definium Therapeutics’s 8 competitors is Minerva Neurosciences, a Formerly VC-backed company based in Burlington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Minerva Neurosciences | Formerly VC-backed | Burlington, MA | ||||
| AtaiBeckley | Formerly VC-backed | New York, NY | ||||
| Seelos Therapeutics | Corporation | New York, NY | ||||
| Voyager Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| ACADIA Pharmaceuticals | Formerly VC-backed | San Diego, CA |
Definium Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Definium Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Definium Therapeutics Investments & Acquisitions (3)
Definium Therapeutics’s most recent deal was a Merger/Acquisition with HealthMode for . The deal was made on 26-Feb-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| HealthMode | 26-Feb-2021 | Merger/Acquisition | Other Healthcare Technology Systems | ||
| Broadway Mining | 28-Feb-2020 | Merger/Acquisition | Multi-line Mining | ||
| Coronado Resources (Madison Gold & Copper Mine) | 21-Jul-2016 | Corporate Asset Purchase | Buildings and Property |
Definium Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
33.9 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Definium Therapeutics Exits (1)
Definium Therapeutics’s most recent exit was on 21-Jul-2016 from Coronado Resources (Madison Gold & Copper Mine). The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Coronado Resources (Madison Gold & Copper Mine) | 21-Jul-2016 | Completed |
|
Definium Therapeutics FAQs
-
When was Definium Therapeutics founded?
Definium Therapeutics was founded in 2019.
-
Where is Definium Therapeutics headquartered?
Definium Therapeutics is headquartered in New York, NY.
-
What is the size of Definium Therapeutics?
Definium Therapeutics has 106 total employees.
-
What industry is Definium Therapeutics in?
Definium Therapeutics’s primary industry is Drug Discovery.
-
Is Definium Therapeutics a private or public company?
Definium Therapeutics is a Public company.
-
What is Definium Therapeutics’s stock symbol?
The ticker symbol for Definium Therapeutics is DFTX.
-
What is the current stock price of Definium Therapeutics?
As of 13-Nov-2026 the stock price of Definium Therapeutics is $32.08.
-
What is the current market cap of Definium Therapeutics?
The current market capitalization of Definium Therapeutics is $4.39B.
-
Who are Definium Therapeutics’s competitors?
Minerva Neurosciences, AtaiBeckley, Seelos Therapeutics, Voyager Therapeutics, and ACADIA Pharmaceuticals are some of the 8 competitors of Definium Therapeutics.
-
What is Definium Therapeutics’s annual earnings per share (EPS)?
Definium Therapeutics’s EPS for 12 months was -$2.92.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
